Formulation Development
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Lisata Therapeutics, Inc. recently announced the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial. This investigator-initiated trial,…
WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at…
Bespak Reaches Key Milestone in the Expansion of its Manufacturing Capacity, with Further Expansion Plans Underway to Meet Global Customer Demand for Climate Friendly Inhalers
Bespak recently announcing progress in its commitment to the production of low global warming potential (GWP) pressurised metered dose inhalers (pMDIs) with the arrival of…
Biora Therapeutics Announces Presentation on the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced it will present preclinical data from the BioJet Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery…
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Tiziana Life Sciences, Ltd. recently announced it has received acceptance of its submission for intranasal foralumab to receive Fast Track Designation approval for the treatment…
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease
Belite Bio, Inc recently announced its lead pipeline, Tinlarebant, has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan (MHLW)…
Enterprise Therapeutics Publishes Preclinical Profile of a Novel Inhaled ENaC Blocker
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis. The paper describes low doses of the…
OBI Pharma Announces Phase 1/2 Study Initiation for a TROP2-Targeted ADC for Cancer Therapy
OBI Pharma recently announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an…
NodThera’s NLRP3 Inhibitor Meets Primary Endpoint of Inflammation Reversal in Phase 1b/2a Trial in Obese Subjects With Cardiovascular Risk
NodThera recently announced positive data from its Phase 1b/2a cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome…
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte Therapy
KSQ Therapeutics, Inc. recently announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of…
XOMA Receives $8.1-Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
XOMA Corporation recently announced it has received an $8.1-million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority…
Wave Life Sciences Announces Presentations Highlighting Novel siRNA Program in Obesity & Leadership in RNA Editing
Wave Life Sciences Ltd. recently announced presentations at the 2nd Annual Obesity & Weight Loss Drug Development Summit and the 5th Annual RNA Editing Summit,…
MD Anderson & Sibylla Biotech Announce Strategic Collaboration to Discover & Develop Small Molecule Protein Degraders
The University of Texas MD Anderson Cancer Center and Sibylla Biotech recently announced a strategic collaboration agreement to discover and develop novel small molecule cancer…
Sermonix Pharmaceuticals Announces Breast Cancer Research Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
Sermonix Pharmaceuticals Inc. recently announced the publication of its scholarly article Lasofoxifene as a Potential Treatment for Aromatase Inhibitor-Resistant ER-Positive Breast Cancer, in the peer-reviewed…
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, recently announced that…
SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild-to-Moderate Alopecia Areata
SiSaf Ltd recently announced that a licensee of the ProSilic variant of its technology has reported positive topline results from a randomized, placebo-controlled, multi-dose Phase 2…
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate
Assembly Biosciences, Inc. recently announced the first participant has been dosed in the Phase 1a/b trial of its long-acting herpes simplex virus (HSV) helicase-primase inhibitor…
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback From Both FDA & EMA
MoonLake Immunotherapeutics recently announced the successful outcome of its end-of-Phase 2 interactions with the US FDA as well as positive feedback from its interactions with…
CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation
CordenPharma and Certest have signed a partnership agreement on May 7, 2024, which aims to add ionizable lipids to CordenPharma’s complex LNP formulation services, the missing….
Atriva Therapeutics Secures US Patent for First-in-Class Broad Spectrum Therapy for Severe RNA Virus Infections Including Bird Flu
Atriva Therapeutics recently announced it has been granted a US patent for its MEK inhibitor zapnometinib (ATR-002). The patent includes claims for the treatment of…
